---
title: 'Uric Acid and SGLT2 Inhibition With Empagliflozin in HeartÂ Failure With Preserved
  Ejection Fraction: The EMPEROR-Preserved Trial'
date: '2024-10-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39453357/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241025210316&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Hyperuricemia is a common complication in HFpEF and is
  related to advanced disease severity and adverse outcome. Empagliflozin induced
  a rapid and sustained reduction of SUA levels and of clinical events related to
  ...'
disable_comments: true
---
CONCLUSIONS: Hyperuricemia is a common complication in HFpEF and is related to advanced disease severity and adverse outcome. Empagliflozin induced a rapid and sustained reduction of SUA levels and of clinical events related to ...